Intestinal subepithelial myofibroblasts in inflammatory bowel disease: fibroblast heterogeneity, fibrosis, and therapeutic targeting - Takeaways - MDSpire

Intestinal subepithelial myofibroblasts in inflammatory bowel disease: fibroblast heterogeneity, fibrosis, and therapeutic targeting

  • By

  • Fang Li

  • Chao Xu

  • Jun Chen

  • Teng Lei

  • Xigui Tian

  • Yuanling Zhang

  • Guoqing Chen

  • June 24, 2026

  • 0 min

Share

  • 1

    Intestinal fibrosis is a significant complication of inflammatory bowel disease (IBD), leading to bowel strictures and impaired function.

  • 2

    Intestinal subepithelial myofibroblasts (ISEMFs) are crucial for epithelial homeostasis, mucosal repair, and extracellular matrix remodeling.

  • 3

    Chronic inflammation can lead to pathological activation of ISEMFs, resulting in excessive matrix deposition and progressive fibrosis.

  • 4

    Recent studies highlight fibroblast heterogeneity and identify specific fibroblast subsets linked to fibrostenotic disease in IBD.

  • 5

    Current therapeutic strategies targeting stromal pathways include antifibrotic agents and cytokine-directed therapies for IBD.

Original Source(s)

Intestinal subepithelial myofibroblasts in inflammatory bowel disease: fibroblast heterogeneity, fibrosis, and therapeutic targeting

  • by Fang Li, Chao Xu, Jun Chen, Teng Lei, Xigui Tian, Yuanling Zhang, Guoqing Chen

  • June 24, 2026

Related Content

The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based study

Editorial: Community series in towards precision medicine for immune-mediated disorders: advances in using big data and artificial intelligence to understand heterogeneity in inflammatory responses, volume III

Casein hydrolysate promotes intestinal repair in adult mice with Salmonella enteritis through a lactate-GPR81-Wnt3A axis in intestinal stem cell niche